LBiome™ (Lactobacillus LB Postbiotic — Stratum Nutrition)

Evidence Level
Limited
1 Clinical Trial
6 Documented Benefits
2/5 Evidence Score

LBiome™ is a proprietary lactobacillus LB postbiotic distributed by Stratum Nutrition — distinguished by a heat-treated (non-living) form of the Lactobacillus LB strain, so it does not depend on viable bacteria and does not need refrigeration. Read the evidence section before buying: all four studies cited on this page were done in children, three of them in short episodes of acute diarrhea and the fourth a systematic review of postbiotics in childhood infectious illness. No cited trial tested adults using it for everyday digestive comfort, and nothing here is a treatment for any illness. Used for: gut health, digestive support, microbiome modulation, postbiotic alternative to live probiotics.

Studied Dose No adult dose is established by the studies cited here; the published trials used the heat-killed preparation in children during an acute illness.
Active Compound Heat-treated Lactobacillus LB cells and culture metabolites

Benefits

Postbiotic Mechanism

Heat-treated (non-living) Lactobacillus LB cells and their culture metabolites are used in place of viable organisms, which is what places this ingredient in the postbiotic category rather than the probiotic one. That is a description of the format. What it does and does not do in people is a separate question, covered in the research section below.

Shelf Stability

Because the cells are already inactivated, there is no live colony count to decline over shelf life, so the material is stable without refrigeration. This is a formulation property rather than a clinical benefit.

Non-Living Format and Bacteremia Concerns

Because the bacteria are heat-killed, they cannot multiply or seed the bloodstream, which is the mechanistic reason the rare bacteremia case reports tied to live probiotics do not apply to this format. That is reasoning about the format, not a tested result: none of the studies cited on this page enrolled immunocompromised participants, so suitability for severely immunocompromised people is not established here. Anyone who is immunocompromised should clear any supplement with their care team first.

Digestive Support

The human research on this strain is pediatric acute-illness research. Heat-killed Lactobacillus acidophilus LB was tested in randomized placebo-controlled trials in children with acute diarrhea, in one case added to standard oral rehydration therapy (PMID 10630442, 17460488, 17768180). None of it examined everyday digestive comfort in healthy adults, and none of it makes this ingredient a remedy for a bowel illness.

Microbiome Modulation

Microbiome modulation is a plausible mechanism, but it is not established by the references on this page. The four cited studies are pediatric acute-illness research with diarrhea and infection outcomes, not studies of gut microbiome composition. Treat this as an untested idea rather than a demonstrated effect.

Sourcing Note, Not a Health Benefit

LBiome is supplied as a branded ingredient by Stratum Nutrition. That is a sourcing and supply-chain fact about who sells the raw material. It is not a health outcome and says nothing about what the ingredient does in the body.

Mechanism of action

1

Heat-Treated Bacterial Components

Heat treatment kills bacteria but preserves bacterial cell wall components, metabolites, and bioactive compounds with biological effects.

2

Immune Modulation Without Live Cells

Bacterial cell wall fragments (peptidoglycans, lipoteichoic acid) modulate immune responses without requiring live organisms.

3

Gut Microbiome Influence

Postbiotic compounds may influence existing gut microbiome composition.

Clinical trials

1
Heat-Killed Lactobacillus acidophilus LB in Children: Acute-Illness Research

Four references, all pediatric. Three are randomized placebo-controlled trials of heat-killed Lactobacillus acidophilus LB in children with acute diarrhea: a 2000 trial adding it to oral rehydration therapy (PMID 10630442), a 2007 multicenter Phase III trial in mild acute diarrhea (PMID 17460488), and a 2007 experimental plus randomized double-blind study of antisecretory activity in nonrotavirus diarrhea (PMID 17768180). The fourth is a 2020 Nutrients systematic review of postbiotics for preventing and treating common infectious diseases in children (PMID 32024037).

Children with acute diarrhea or common infectious illness. No cited study enrolled adults, and none enrolled immunocompromised participants.

These were clinical trials in children who were acutely ill, one of them adding the heat-killed preparation to oral rehydration therapy, and the systematic review pools that kind of pediatric evidence at the class level. Two limits matter for anyone buying this as a daily supplement. First, an acute illness in a child is not the same setting as an adult's routine digestion, so these results do not transfer to general gut comfort. Second, treating diarrhea or an infection is a disease claim, and this page does not make one. Acute diarrhea, particularly with dehydration, blood in the stool, high fever, or symptoms lasting more than a couple of days, needs a clinician rather than a supplement.

Side effects and drug interactions

Common Potential side effects

Generally extremely well-tolerated.
Mild GI distress (rare).
Allergic reactions extremely rare.
Postbiotic format contains no live bacteria, so the rare bacteremia reports linked to live probiotic organisms do not apply. This follows from the format and was not specifically tested in high-risk participants in any study cited here.

Important Drug interactions

Generally minimal drug interactions.
Pregnancy — limited specific safety data; postbiotic mechanism generally safer than live probiotics.
Lactation — generally safe.
Children — the published trials on this strain were run in children with acute diarrhea under medical supervision, not as routine daily supplementation. Ask a pediatrician before giving it to a child, and seek care rather than self-treating a child's diarrhea.
Immunocompromised — the inactivated format removes the live-organism concern that makes probiotics cautionary for this group, but no cited study enrolled immunocompromised people. Treat it as reasoning rather than evidence and check with the treating physician first.

Frequently asked questions about LBiome™ (Lactobacillus LB Postbiotic — Stratum Nutrition)

What is LBiome?

LBiome™ is a proprietary lactobacillus LB postbiotic distributed by Stratum Nutrition — distinguished by a heat-treated (non-living) form of the Lactobacillus LB strain, so it does not depend on viable bacteria and does not need refrigeration.

What is LBiome used for?

LBiome is researched primarily for Gut Health. Heat-treated (non-living) Lactobacillus LB cells and their culture metabolites are used in place of viable organisms, which is what places this ingredient in the postbiotic category rather than the probiotic one.

What is the recommended dosage of LBiome?

The clinically studied dose is No adult dose is established by the studies cited here; the published trials used the heat-killed preparation in children during an acute illness. Always follow the product label and check with a healthcare provider for personal advice.

Is LBiome safe, and does it have side effects?

For most healthy adults, LBiome is well tolerated at studied doses. Reported effects can include: Generally extremely well-tolerated. Mild GI distress (rare). It may also interact with some medications. LBiome is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does LBiome interact with any medications?

Possible interactions include: Generally minimal drug interactions. Pregnancy — limited specific safety data; postbiotic mechanism generally safer than live probiotics. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for LBiome?

NutraSmarts rates the evidence for LBiome as Limited (2 out of 5). It is backed by 1 clinical trial and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Simakachorn N, Pichaipat V, Rithipornpaisarn P, Kongkaew C, Tongpradit P, Varavithya W Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children J Pediatr Gastroenterol Nutr. 2000;30(1):68-72. doi: 10.1097/00005176-200001000-00020.PubMedUsed to support: Human placebo-controlled clinical trial of heat-killed Lactobacillus acidophilus LB (the same strain in LBiome/Lacteol) for acute pediatric diarrhea — directly supporting digestive support and postbiotic mechanism claims.
  2. Salazar-Lindo E, Figueroa-Quintanilla D, Caciano MI, Reto-Valiente V, Chauviere G, Colin P; Lacteol Study Group Effectiveness and safety of Lactobacillus LB in the treatment of mild acute diarrhea in children J Pediatr Gastroenterol Nutr. 2007;44(5):571-6. doi: 10.1097/MPG.0b013e3180375594.PubMedUsed to support: Placebo-controlled human RCT of Lactobacillus LB (Lacteol, same heat-killed strain) for acute pediatric diarrhea, demonstrating effectiveness and safety — supporting digestive support benefit and immunocompromised-suitable non-viable form.
  3. Liévin-Le Moal V, Sarrazin-Davila LE, Servin AL An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of Lactobacillus acidophilus strain LB against nonrotavirus diarrhea Pediatrics. 2007;120(4):e795-803. doi: 10.1542/peds.2006-2930.PubMedUsed to support: Randomized double-blind placebo-controlled trial of heat-killed L. acidophilus LB for nonrotavirus diarrhea in children, demonstrating antisecretory activity — supporting postbiotic mechanism and digestive support claims.
  4. Malagón-Rojas JN, Mantziari A, Salminen S, Szajewska H Postbiotics for Preventing and Treating Common Infectious Diseases in Children: A Systematic Review Nutrients. 2020;12(2):389. doi: 10.3390/nu12020389.PubMedUsed to support: Systematic review pooling RCT evidence for heat-killed/inactivated Lactobacillus (including L. acidophilus LB) in pediatric infectious diarrhea — supporting postbiotic mechanism, shelf stability advantages, and digestive support as class-level evidence.